60-70% ofpatients withCML presentwith thissymptomWhen togive H2RAswithdasatinibResponsewhen BCR-ABL1 (IS)is <0.01%I have theT315I mutationbut also haveelevated lipaseTKIs aremajorsubstratesfor this liverenzymeThelandmarkfor thefirst TKIThis TKI hasthe mostmetabolicsyndromeThe current5-yearoverallsurvival rateof CMLNon-pharmacologicaltreatment forCMLTranslocationbetweenthese twochromosomesoccur in CMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibPatients havepresence of thisBCR-ABLproteinindicative ofCML The numberof distinctclinicalphases inCMLTherecommendedcriteria usedfor acceleratedphaseModerateto highemetogenicrisk TKIsPercentageof blastspresent inthe blastphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseNumber ofblastspresent inacceleratedphaseThe scoringsystem usedin chronicphaseI failed 3lines of TKIs,I can try thisagent nextI want toavoid thisTKI if I donot wantdiarrheaDrug classthatrevolutionizedCMLtreatmentTreatmentfor blastphaseCMLToo many ofthese bloodcells areabnormal inCML60-70% ofpatients withCML presentwith thissymptomWhen togive H2RAswithdasatinibResponsewhen BCR-ABL1 (IS)is <0.01%I have theT315I mutationbut also haveelevated lipaseTKIs aremajorsubstratesfor this liverenzymeThelandmarkfor thefirst TKIThis TKI hasthe mostmetabolicsyndromeThe current5-yearoverallsurvival rateof CMLNon-pharmacologicaltreatment forCMLTranslocationbetweenthese twochromosomesoccur in CMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibPatients havepresence of thisBCR-ABLproteinindicative ofCML The numberof distinctclinicalphases inCMLTherecommendedcriteria usedfor acceleratedphaseModerateto highemetogenicrisk TKIsPercentageof blastspresent inthe blastphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseNumber ofblastspresent inacceleratedphaseThe scoringsystem usedin chronicphaseI failed 3lines of TKIs,I can try thisagent nextI want toavoid thisTKI if I donot wantdiarrheaDrug classthatrevolutionizedCMLtreatmentTreatmentfor blastphaseCMLToo many ofthese bloodcells areabnormal inCML

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
G
2
G
3
B
4
N
5
I
6
G
7
O
8
I
9
O
10
G
11
I
12
B
13
O
14
N
15
G
16
B
17
I
18
O
19
B
20
O
21
B
22
N
23
I
24
N
  1. G-60-70% of patients with CML present with this symptom
  2. G-When to give H2RAs with dasatinib
  3. B-Response when BCR-ABL1 (IS) is <0.01%
  4. N-I have the T315I mutation but also have elevated lipase
  5. I-TKIs are major substrates for this liver enzyme
  6. G-The landmark for the first TKI
  7. O-This TKI has the most metabolic syndrome
  8. I-The current 5-year overall survival rate of CML
  9. O-Non-pharmacological treatment for CML
  10. G-Translocation between these two chromosomes occur in CML
  11. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  12. B-Patients have presence of this BCR-ABL protein indicative of CML
  13. O-The number of distinct clinical phases in CML
  14. N-The recommended criteria used for accelerated phase
  15. G-Moderate to high emetogenic risk TKIs
  16. B-Percentage of blasts present in the blast phase
  17. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  18. O-Number of blasts present in accelerated phase
  19. B-The scoring system used in chronic phase
  20. O-I failed 3 lines of TKIs, I can try this agent next
  21. B-I want to avoid this TKI if I do not want diarrhea
  22. N-Drug class that revolutionized CML treatment
  23. I-Treatment for blast phase CML
  24. N-Too many of these blood cells are abnormal in CML